INFU

InfuSystem Holdings Inc

Add to Watchlist

Advanced Chart

5.900

-0.11(-1.830%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.005

Open

5.930

VWAP

Vol

116.00K

Mkt Cap

123.75M

Low

5.885

Amount

EV/EBITDA(TTM)

7.18

Total Shares

21.30M

153.26M

EV/OCF(TTM)

7.01

P/S(TTM)

0.94

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

38.18M

+12.8%

37.87M

+7.22%

36.14M

+7.25%

Estimates Revision

The market is revising Upward the revenue expectations for InfuSystem Holdings, Inc. (INFU) for FY2025, with the revenue forecasts being adjusted by 0.28% over the past three months. During the same period, the stock price has changed by 19.92%.

Revenue Estimates for FY2025

Revise Upward

+0.28%

In Past 3 Month

Stock Price

Go Up

+19.92%

In Past 3 Month

3 Analyst Rating

107.63% Upside

Wall Street analysts forecast INFU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INFU is 12.25 USD with a low forecast of 12.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

107.63% Upside

Current: 5.900

Low

12.00

Averages

12.25

High

12.50

107.63% Upside

Current: 5.900

Low

12.00

Averages

12.25

High

12.50

Roth Capital

Kyle Bauser

Buy

initiated

$12

2025-07-21

Reason

Roth Capital

Kyle Bauser

Price Target

$12

2025-07-21

initiated

Buy

Reason

Roth Capital analyst Kyle Bauser initiated coverage of InfuSystem with a Buy rating and $12 price target. InfuSystem operates two key segments - Patient Services and Device Solutions - and the company's ability to automate billing, patient records, and pump tracking allows it to serve a larger base without linearly scaling headcount, the analyst tells investors. The firm believes the company can drive further margin expansion from more efficient operations and additional scale, the analyst added.

B. Riley

Buy

downgrade

$14 -> $12

2025-05-09

Reason

B. Riley

Price Target

$14 -> $12

2025-05-09

downgrade

Buy

Reason

B. Riley lowered the firm's price target on InfuSystem to $12 from $14 and keeps a Buy rating on the shares following the Q1 report. The company remains focused on improving profitability while pursuing growth opportunities such as advanced wound care and chemo mouthpiece, the analyst tells investors in a research note. Riley expects InfuSystem to continue to repurchase shares throughout the year.

See All Ratings

Valuation Metrics

The current forward P/E ratio for InfuSystem Holdings Inc (INFU.A) is 36.42, compared to its 5-year average forward P/E of 81.04. For a more detailed relative valuation and DCF analysis to assess InfuSystem Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

81.04

Current PE

36.42

Overvalued PE

149.49

Undervalued PE

12.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

10.09

Current EV/EBITDA

5.60

Overvalued EV/EBITDA

13.08

Undervalued EV/EBITDA

7.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

1.90

Current PS

0.85

Overvalued PS

2.79

Undervalued PS

1.01